Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial
The Lancet - United Kingdom
doi 10.1016/s0140-6736(11)60545-x
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 1, 2011
Authors
Publisher
Elsevier BV